Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010
Current Assets:
Cash and cash equivalents	$ 67,049	$ 53,557
Marketable securities	37,388	42,117
Accounts receivable, net of allowance for doubtful accounts of $630 and $339, respectively	46,471	21,051
Inventories, net	9,399	4,234
Prepaid expenses and other current assets	883	906
Total current assets	161,190	121,865
Investments	14,095	8,569
Property and equipment, net	3,050	3,158
Intangible assets, net	43,962	29,605
Other assets	379	434
TOTAL ASSETS	222,676	163,631
Current Liabilities:
Accounts payable and other accrued obligations	56,539	38,704
Accrued compensation and related expenses	2,816	3,313
Deferred revenue	12,300	12,300
Common stock warrant liability	10,391	3,904
Accrued drug development costs	7,163	5,101
Total current liabilities	89,209	63,322
Capital lease obligations	25	40
Deferred revenue and other credits--less current portion	19,290	25,495
Zevalin related contingent obligations	298	298
Total liabilities	108,822	89,155
Commitments and contingencies
Stockholders' Equity:
Preferred stock value	0	0
Common stock, $0.001 par value--175,000,000 shares authorized; 52,947,221 and 51,459,284 issued and outstanding at June 30, 2011 and December 31, 2010, respectively	53	51
Additional paid-in capital	404,273	384,757
Accumulated other comprehensive loss	(176)	(92)
Accumulated deficit	(290,419)	(310,400)
Total stockholders' equity	113,854	74,476
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	222,676	163,631
Series E convertible preferred stock
Stockholders' Equity:
Preferred stock value	$ 123	$ 160